PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(05): 409-414
DOI: 10.1055/s-0042-1748802
Original Article

A Prospective Single-Arm Study of Melphalan, Prednisolone and Lenalidomide (MPL) as First Line Treatment in Elderly Patients with Multiple Myeloma – An Institutional Study

Haridas K. Lakshmi
1   Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, India
,
Geetha Narayanan
1   Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, India
,
Shahid P. P. Abdul
2   Department of Medical Oncology, Kerala Institute of Medical Sciences (KIMS), Trivandrum, Kerala, India
,
G. Nair Sreejith
1   Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, India
› Institutsangaben Funding None.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Introduction Multiple myeloma in the elderly population is rising in India. Such frail transplant-ineligible patients are less frequently included in clinical trials. Moreover, novel agents are not accessible to everyone. Melphalan-based chemotherapy regimens are frequently used in elderly myeloma patients. Our study revisited the role of melphalan, prednisone, and lenalidomide (MPL) as front-line therapy in this subgroup of patients.

Objective The aim of this study was to determine the response, tolerance, and outcome of MPL in elderly patients with newly diagnosed multiple myeloma.

Materials and Methods This prospective study was conducted at the Department of Medical Oncology at a tertiary cancer center during January 2012 to September 2013. Newly diagnosed patients with multiple myeloma >60 years who were transplant ineligible formed the study subjects. Eligible patients received oral melphalan 0.18 mg/kg from D1 to 4, prednisone 2 mg/kg from D1 to 4, and lenalidomide 10 mg from D1 to 21 q28 days. Patients who achieved complete response/very good partial response (CR/VGPR) after 6 cycles of MPL received maintenance with lenalidomide 10 mg from D1 to 21 q28 days (MPL-L) until progression or 1 year whichever was earlier. Quality of life was assessed using the Eq. 5D questionnaire.

Results Out of 46 patients, 25 were males and 21 were females. Median age was 67 years (range: 60—83 years). Majority had immunoglobulin G myeloma, followed by immunoglobulin A subtype. The median quality of life score at baseline was 50 (range: 30–70). Forty patients completed six cycles of MPL. The main toxicity was grade 1 to 2 hematological. There were no treatment-related deaths. Twenty-two (55%) achieved CR, 5 (13%) achieved VGPR, 4 (10%) achieved partial response, 6 (15%) achieved stable disease, and 3 (7%) had progressive disease. Twenty-seven patients received lenalidomide maintenance. At a median follow-up of 55 months, the 2- and 5-year progression-free survival was 60 and 18%, respectively. The overall survival at 2 and 5 years were 80 and 53%, respectively. The median number of subsequent lines of treatment was 2 (range: 1–4). The quality of life was improved and preserved in all study subjects. At 8 years, three patients had second malignant neoplasms and seven are alive.

Conclusion MPL-L is a well-tolerated and effective regimen in elderly myeloma with good overall response rates.

Keywords

MPL - elderly myeloma - lenalidomide maintenance


Publikationsverlauf

Artikel online veröffentlicht:
20. Oktober 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kumar L, Nair S, Vadlamani SP, Chaudhary P. Multiple myeloma: an update. J Curr Oncol 2020; 3: 72-80
    CrossrefGoogle Scholar
  • 2 Greipp PR, San Miguel J, Durie BG. et al. International Staging System for Multiple Myeloma. J Clin Oncol 2005; 23 (15) 3412-3420
    CrossrefPubMedGoogle Scholar
  • 3 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12) e538-e548
    Google Scholar
  • 4 Preedy VR, Watson RR. EQ-5D. Handbook of Disease Burdens and Quality of Life Measures. 2010. Springer; NY: https://doi.org/10.1007/978-0-387-78665-0_5607
    CrossrefGoogle Scholar
  • 5 Facon T, Mary JY, Hulin C. et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; ; 6;370(9594): 1209-1218 DOI: 10.1016/S0140-6736(07)61537-2.
    CrossrefPubMedGoogle Scholar
  • 6 Palumbo A, Falco P, Corradini P. et al; GIMEMA–Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol 2007; 25 (28) 4459-4465
    CrossrefPubMedGoogle Scholar
  • 7 Roy V, Stewart A, Bergsagel P. et al. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation [abstract]. Blood. 2008 ; 112 Abstract 2769.
    PubMedGoogle Scholar
  • 8 Stewart A, Jacobus S, Fonseca F. et al. E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM) [Abstract]. J Clin Oncol.. 2014 ; 32 (5 s_suppl) Abstract 8511.
    PubMedGoogle Scholar
  • 9 Palumbo A, Hajek R, Delforge M. et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366 (19) 1759-1769
    CrossrefPubMedGoogle Scholar
  • 10 Stewart AK, Jacobus S, Fonseca R. et al. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 2015; 126 (11) 1294-1301
    CrossrefPubMedGoogle Scholar